scholarly journals Prediction of Esophagogastric Varices Associated with Oxaliplatin Administration

2021 ◽  
Author(s):  
Yosuke Satta ◽  
Ryuta Shigefuku ◽  
Tsunamasa Watanabe ◽  
Takuro Mizukami ◽  
Takashi Tsuda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Portal Hypertension ◽  
Operating Characteristic ◽  
Characteristic Curve ◽  
Platelet Counts ◽  
Contrast Enhanced ◽  
Esophagogastric Varices ◽  
Operating Characteristic Curve ◽  
Enhanced Computed Tomography ◽  
Contrast Enhanced Computed Tomography

Abstract Background: Oxaliplatin is a key drug for the chemotherapy of colorectal cancer; however, it is also known to cause non-cirrhotic portal hypertension. We aimed to identify the characteristics of patients who developed esophagogastric varices (EGV) after treatment with oxaliplatin.Methods: This study retrospectively analysed patients with colorectal cancer who were treated with chemotherapy including oxaliplatin between 2010 and 2016. All patients were evaluated by contrast-enhanced computed tomography (CT) every 3 months both during and after treatment, and endoscopy was performed when appearance of portal hypertension was suspected.Results: A total of 106 patients were divided into 2 groups: EGV formation (n=6) and EGV non-formation (n=100). In the EGV group, platelet counts decreased and the size of the spleen calculated by CT (CT-SI) increased markedly. The highest area under the receiver operating characteristic curve (AUC) for the change in platelet counts was 0.81 (80% sensitivity and 83% specificity) at 3 months posttreatment and the maximum AUC for CT-SI was 0.89 (79% sensitivity and 83% specificity) at 6 months posttreatment.Conclusions: EGV formation could be predicted by assessment of platelet counts and CT-SI not only during but also after completion of the treatment.

scholarly journals Conventional Laboratory Blood Indicators Are Valuable for Early Diagnosis of Colorectal Cancer

2021 ◽  
Author(s):  
Xia Gan ◽  
Zhi-Yong Chen ◽  
Zi-Hua Li ◽  
Jian-Ming Zhou ◽  
Ying Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Diagnosis ◽  
Receiver Operating Characteristic Curve ◽  
Operating Characteristic ◽  
Clinical Laboratory ◽  
Characteristic Curve ◽  
Diagnostic Value ◽  
Imaging Data ◽  
Operating Characteristic Curve ◽  
Better Than

Abstract Objective: Some conventional laboratory indicators have been found to be of value for the diagnosis of colorectal cancer (CRC). The present study aimed to systematically analyze the diagnostic value of conventional laboratory blood indicators for CRC, especially for early CRC. Methods: A total of 505 patients with CRC (n=210), colorectal adenoma (CRA) (n=167) or polyp (CRP) (n=128) were retrospectively collected. Clinical, laboratory and imaging data available before treatment were extracted. The diagnostic performances of laboratory blood indicators for discriminating total and early CRCs from CRA and CRP (CRA&P) were evaluated.Results: Fifty-three of 76 (69.7%) laboratory blood indicators were significant for discriminating CRC from CRA&P with areas under the receiver operating characteristic curve (AUC) ranging within 0.554-0.819, of these indicators, 17 had AUC > 0.7, three had AUC > 0.8, and five had AUCs greater than that for carcinoembryonic antigen (CEA). Fifteen indicators had overall sensitivities comparable to CEA for the diagnosis of CRC (35.7-55.4% vs. 47.7%, all P>0.05) at a specificity of 90%, and they were not or weakly correlated with CEA (absolute r = 0.058-0.333). For differentiating early CRC (TNM stage I+II, n=102) from CRA&P, the sensitivities for the 15 indicators ranged within 30.4%-55.5% at a specificity of 90% and similar to stage III+IV CRC.Conclusion: Conventional laboratory blood indicators are valuable for early CRC diagnosis, and are comparable to or better than CEA.

Impact of contrast-enhanced computed tomography colonography on laparoscopic surgical planning of colorectal cancer

2013 ◽  
Vol 38 (5) ◽  
pp. 1024-1032 ◽  
Author(s):  
Nicola Flor ◽  
Andrea Pisani Ceretti ◽  
Miriam Mezzanzanica ◽  
Paolo Rigamonti ◽  
Mauro Peri ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Surgical Planning ◽  
Computed Tomography Colonography ◽  
Contrast Enhanced ◽  
Enhanced Computed Tomography ◽  
Contrast Enhanced Computed Tomography

scholarly journals RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Olivier Lucidarme ◽  
Mathilde Wagner ◽  
Paul Gillard ◽  
Stefano Kim ◽  
Jean-Baptiste Bachet ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Objective Response ◽  
Prospective Multicenter Study ◽  
Intention To Treat ◽  
Recist 1.1 ◽  
Contrast Enhanced ◽  
Choi Criteria ◽  
Enhanced Computed Tomography ◽  
Contrast Enhanced Computed Tomography

Abstract Background To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC). Methods Baseline and 2-month contrast-enhanced computed-tomography (CECT) scans of 55 patients with mCRC, prospectively enrolled in phase II TEXCAN trial, were centrally assessed. The primary endpoint was 2-month ORR by RECIST 1.1, Choi, and mChoi criteria. Final outcome was overall survival (OS). Results Of 55 patients included in this study (Intention-to-treat [ITT1] population), 35 had CECT at 2 months (ITT2 population). According to RECIST 1.1 criteria, 20 (57%) patients were SD and 15 were PD (43%) in the ITT2 population. According to Choi criteria, 18 (51%) patients were responders and 17 (48%) were non-responders. Median OS was 5.3 months (95% CI 3.7–8.6) in the ITT1 population and 8.9 months (95% CI 5.1–12.6) in the ITT2 population. In the ITT2 population, median OS was 16 months (95% CI 6.6–17.5) in SD patients (n = 20) and 4.6 months (95% CI 3.3–5.8) in PD patients (n = 15), according to RECIST 1.1 criteria (HR = 6.48). Median OS was 7.9 months (95% CI 4.2–17.5) in responders (n = 18) and 9.9 months (95% CI 3.7-NA) in non-responders (n = 17) according to Choi criteria (HR = 1.06). All patients except one were classified as non-responders with mChoi criteria. Conclusion At 2 months, unlike RECIST 1.1, Choi and mChoi criteria could not identify mCRC patients with regorafenib survival benefit. Trial registration ClinicalTrials.gov Identifier: NCT02699073.Registered March 4, 2016, Retrospectively registered.

Sign in / Sign up

Export Citation Format

Share Document